- BioVaxys Technology Corp. (BIOV) and Ohio State University have made progress on creating a universal vaccine to treat a broad range of SARS viruses
- BioVaxys is a clinical-stage biotechnology company developing vaccines
- It just completed the preparation of the surrogate virus neutralization assays for COVID-19 variants
- The company’s next step will be immunizing test animals with its BVX-1021 vaccine
- It is expecting to see the data from this test trial sometime during August
- BioVaxys Technology Corp. (BIOV) is unchanged trading at $0.11 per share as of 2:48 p.m. ET
BioVaxys (BIOV) and Ohio State University report progress on a universal vaccine to treat a range of SARS viruses.
BioVaxys is a Vancouver-based clinical stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
According to BioVaxys, it has completed preparation of the surrogate virus neutralization assays for the COVID-19 variants, including those that are transmitted between pangolins and bats. The company’s next step will be immunizing test animals with BVX-1021, its “booster” vaccine which will be given alongside established COVID-19 vaccines.
BVX-1021 is undergoing continuous research collaboration between Ohio State and BioVaxys. The partnership started earlier this year. The tests will use a guinea pig model.
The companies goals of the study are the development of virus-neutralizing antibodies to live virus SARS viruses.
Recent yields of the company’s recombinant SARS-1 protein obtained from an external supplier to use for BVX-1021 production were determined to contain the presence of a natural protein aggregate byproduct in addition to the SARS-1 protein.
“Our team felt it prudent for scientific reproducibility to re-synthesize a new yield of recombinant SARS-1 protein specifically screening out the extraneous protein aggregate,” Kenneth Kovan, President and COO of BioVaxys, said.
“The COVID-19 lockdown situation in Shanghai further impacted the lead time for production of the SARS-1 protein by our Shanghai-based supplier.”
BioVaxys is expecting to see the data from this test trial sometime during August.
BioVaxys Technology Corp. (BIOV) is unchanged trading at $0.11 per share as of 2:48 p.m. ET.
